Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A case report of pulmonary sarcoidosis with fibrosis after COVID-19 is presented. Morphologic and immunohistochemical analysis of lung biopsies for Sars-Cov2 nucleocapsid and adhesion proteins was performed. Virus proteins were detected in alveolar macrophages, second-order pneumocytes and bronchiolar epithelium, also in granuloma-associated macrophages, multinucleated Pirogov-Langhans cells, indicating Sars-Cov2 persistence. Meanwhile, release of pro-inflammatory cytokines by granuloma cells and interstitial macrophages resulted in tissue damage and pulmonary fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/patol20258704154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease.
Immune Netw
August 2025
Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for Prevention of Human Diseases, UTHealth-McGovern Medical School, Houston, TX 77030, USA.
Complement anaphylatoxins C3a and C5a are potent immunomodulators whose impact extends well beyond their traditional roles in innate immunity. Acting through G protein-coupled receptors C3aR, C5aR1, and C5aR2, these peptides take part in coordinating immune cell recruitment, vascular tone, and tissue remodeling. Yet their functions are deeply context-dependent: while they play essential roles in microbial clearance and immune coordination, their overactivation contributes to immunopathology in a wide range of diseases.
View Article and Find Full Text PDFEvolving cystic fibrosis care models in the modulator era.
Curr Opin Pulm Med
September 2025
Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.
Purpose Of Review: The advent of CFTR modulators and the adoption of telemedicine during the COVID-19 pandemic have prompted reconsideration of cystic fibrosis (CF) care models. This review explores how care delivery may evolve in response to these changes.
Recent Findings: Emerging evidence highlights the heterogeneity in response to CFTR modulators, with some patients continuing to experience disease progression.
Background: Central centrifugal cicatricial alopecia (CCCA) is a scarring alopecia primarily affecting Black women. To date, there are no standardized treatment regimens or approved medications for the treatment of CCCA. This single-center, open-label, clinical study investigated the efficacy of apremilast in the treatment of mild to moderate vertex-predominant CCCA.
View Article and Find Full Text PDFCOVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID.
J Cyst Fibros
September 2025
Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
Background: The long-term clinical consequences of COVID-19 in cystic fibrosis (CF) remain largely unexplored. This study aimed to assess the incidence of long COVID in a large population of people with CF.
Methods: This prospective, multicentre study enrolled individuals with confirmed SARS-CoV-2 infection between July 2021 and October 2022.
Changing landscape of steatotic liver diseases and liver fibrosis in the United States during the COVID-19 pandemic.
Hepatol Commun
September 2025
Department of Internal Medicine, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: Steatotic liver diseases (SLDs) and their subcategories-metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD)-significantly contribute to liver-related and extrahepatic morbidity and mortality. This project aimed to assess the landscape of SLDs and clinically significant fibrosis (CSF) before (2017-2020) and during (2021-2023) the COVID-19 pandemic.
Methods: Using National Health and Nutrition Examination Survey (NHANES) data, we analyzed 8965 prepandemic and 6337 pandemic participants aged ≥18 years.